101 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
19 Mar 24
Regulation FD Disclosure
6:00am
) for booster vaccination conducted in Japan.
In the phase III clinical study, immunogenicity and safety of a bivalent version of Kostaive® (ARCT-2301 … and Wuhan strain). There were no causally-associated severe or serious adverse events with ARCT-2301.
These results support immunogenicity and safety
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
7 Mar 24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
4:05pm
as well as a Phase 3 COVID-19 booster trial, which achieved higher immunogenicity results and a favorable safety profile compared to a standard mRNA
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
of the safety and tolerability of ARCT-032 in patients. It advances our effort to provide benefit to the CF population with the largest unmet need
8-K
EX-99.1
rrz3i5ri
26 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-99.1
y2x7qyzb9a sqgx
7 Aug 23
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
4:23pm
8-K
0prob50
14 Jul 23
Regulation FD Disclosure
7:53am
8-K
EX-99.1
6ht5ed7a2f8b4gps2y1e
30 Jun 23
Regulation FD Disclosure
8:28am
8-K
EX-99.1
ktyc87wxzdy
9 May 23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
4:11pm
8-K
EX-99.1
sm37419
28 Apr 23
Regulation FD Disclosure
6:00am